PR
Media
-
HEM Pharma Received Approval from the U.S. Food and Drug Administration for Phas..2023.06.07 -
[Monthly Magazine] Hankyung Bio Insight May Issue Interview with CEO2023.05.25 -
HEM Pharma, selected for the 'microbiome-based original technology development' ..2023.05.02 -
HEM Pharma, selected as a project to establish a foundation for personalized nut..2023.05.02 -
[Seminar] Microbiome industry seminar successfully completed2023.04.05 -
HEM Pharma submits IND for phase 2a clinical trial of a new antidepressant candi..2023.03.14 -
HEM Pharma approved for phase 2 clinical trial in Australia for treatment of low..2023.03.06 -
[Monthly Magazine] Interview with CEO Josep Ji of Monthly People, February2023.02.10 -
[Broadcast] PAX Economic TV "Close-up corporate site"2023.01.25 -
HEM Pharma “Strengthening Microbiome Business Competitiveness”2023.01.25 -
HEM Pharma, signs a business agreement with LogMe for the development of health..2022.12.05 -
[Broadcast] 'Hope TV SBS' Sharing to save the world - Eco-friendly management c..2022.11.24
- Headquarters
-
Address. #711, Flex Desiang, 50, Changnyong-daero 256beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, Republic of Korea
- Gwanggyo Office
- Address. #404, Ace Gwanggyo Tower 3, 77, Changnyong-daero 256beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, Republic of Korea
(C) 2022.HEM Pharma Inc. All rights reserved.